Objective: To evaluate the efficacy and safety of a novel tomato-based food supplement on the lower urinary tract symptoms (LUTS) of patients with benign prostatic hyperplasia (BPH).
Introduction
Benign prostatic hyperplasia BPH affects aging men and represents the most common urologic disease among elderly men 1 . BPH is a growth of both epithelial and stromal cells from both the transition zone and periurethral areas, and typically develops after the age of 40 years, ranging in prevalence from >50% at 60 years to as high as 90% by 85 years of age 2 .
The diagnosis of BPH is often in response to the development of lower urinary tract obstructive, irritative, and post-micturition symptoms (LUTS), including urinary hesitancy, urgency, frequency and post void dribble.
Medical treatment options include α-adrenergic
antagonists or 5-α reductase inhibitors, however about one-third of men with LUTS do not respond to either treatment approach 3 . Patients who are resistant to treatment, or who become resistant to treatment over time, will become candidates for surgical intervention to reduce LUTS severity.
Further understanding the causes of LUTS will guide interventions to prevent LUTS or increase sensitivity to medical treatment. To date, there are multiple theories on the cellular and molecular processes underlying the pathogenesis of BPH leading to a symptomatic disease. In addition to androgens, both chronic and acute inflammation can lead to events that can cause proliferation within prostatic tissue through a variety of mechanisms, notably oxidative stress [4, 5] . At present, non-steroidal anti-inflammatory drugs are used to improve urinary symptoms and flow measures, but their long-term effectiveness and safety are not known 6 .
BPH is also associated with obesity and related pathologies. However, the biological pathways linking obesity and BPH are poorly understood. Centralized adipose deposition was associated with the severity of prostate tissue inflammation and LUTS and an approach to minimize centralized fat deposition may reduce LUTS severity in BPH patients 7 .
A large number of anti-inflammatory compounds has been identified in tomato extracts 8 ; moreover, tomato consumption reduces inflammation by decreasing inflammatory cytokines in overweight and obese humans [9, 10] .
We have also observed that a feed enriched with a 10% whole tomato preparation versus a tomato-free control feed is able to increase the anti-oxidant serum activity and to reduce serum levels of inflammatory biomarkers in the TRAMP mouse model of prostate carcinogenesis, even before the appearance of cancer 11 .
Recently, a novel food supplement named Lycoprozen® was developed by Janus Pharma, Roma,
Italy. It consists of whole tomatoes specially processed for make their antioxidant and anti-inflammatory micronutrients highly bioavailable, and a small percentage of olive's vegetation water. In the present study, we have evaluated the effects of Lycoprozen® on the LUTS severity in subjects affected by BPH.
Materials and Methods
Lycoprozen® is available as food supplement The compositions of the tomato powder and polyphenolic extract from olive vegetation water are reported in Table 1 and in Table 2 , respectively.
Patients
Twenty patients with BPH were enrolled in this observational study. All patients underwent clinical and instrumental examinations and completed the IPSS (International Prostatic Symptom Score) questionnaire 13 .
Furthermore, patients were informed both orally and by means of a written informed consent form. They were assigned to receive an oral sachet of Lycoprozen® (5 grams) every 24 hours, for two months. The main outcome measures were a reduction of LUTS and improved quality of life at the end of the study period.
Results
All patients successfully completed treatment with no side effects.
The IPSS is based on the answer to seven questions concerning urinary symptoms, and is the only 
Discussion
As reported above, Lycoprozen® is a mixture of two components, tomato powder and a polyphenolic extract from olives. The present observational study revealed that a once-daily intake of Lycoprozen® for two months significantly improved urinary symptoms and quality of life in patients with BPH.
BPH has been shown to be associated with an inflammatory environment, which is known to sustain proliferative programs resulting in nodules of BPH [4, 5, 15] and the anti-angiogenic/anti-inflammatory activities of tomato could represent the basis of its beneficial effect on BPH [8, 9, 10, 11] .
Conclusion
Based on these preliminary data, Lycoprozen® may be a suitable alternative option for the treatment of symptomatic BPH patients. The treatment was without side effects and acceptance among patients was high.
Limitations of the Study and Ongoing Activities
The aim of the present study was to assess the 
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